scholarly journals Platelet-to-Lymphocyte Ratio (PLR) Profile and Neutrophil-to-Lymphocyte Ratio (NLR) in Lung Cancer Patients in Ulin General Hospital Banjarmasin 2017-2018

2020 ◽  
Vol 16 (1) ◽  
pp. 25
Author(s):  
Haryati Haryati ◽  
Holly Diany
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
General Hospital ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Stage ◽  
Platelet To Lymphocyte Ratio ◽  
Lung Cancer Patients ◽  
Lymphocyte Ratio ◽  
Anatomy Laboratory ◽  
End Stage

Abstract: Lung cancer is the leading cause of malignancy in the world reaching up to 13% of all cancer diagnoses. Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR), are promising markers of inflammatory prognosis, clinical decisions for proper management of lung cancer patients. The research used a retrospective analytic observational study as its research method. Samples were taken from Pathology Anatomy Laboratory, and the medical record data of lung cancer patients in Ulin General Hospital Banjarmasin from 2017 to 2018. Male lung cancer patients have percentage of 72% with PLR NLR values by sex are not much different p>0.05. 23% of patients were aged ≥ 65 years and 77% were aged £ 65 years with value p>0.05. Adenocarcinoma reaches 65% with p>0.05. Most metastases are 44% pleural effusion with value p>0.05. Percentage of advanced stage is 90% with a higher PLR NLR value at the end stage. There is a meaningful relationship of NLR with lung cancer stage p<0.05, but no relantionship with PLR p>0.05. PRL and NRL are increased at advanced stage. NRL and PRL did not differ significantly based on age, sex and histology of lung cancer. Keywords: Platelet-to-lympho­cyte ratio (PLR), Neutrophil-to-lymphocyte ratio (NLR), lung cancer

scholarly journals Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Blood to Distinguish Lung Cancer Patients from Healthy Subjects

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Xuming Zhu ◽  
Huizhu Song ◽  
Yan Chen ◽  
Feifei Han ◽  
Qiong Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Control Group ◽  
Healthy Individuals ◽  
Platelet To Lymphocyte Ratio ◽  
Lung Cancer Patients ◽  
Lymphocyte Ratio ◽  
Cancer Group ◽  
Level Group

Objective. Inflammation-driven markers play a crucial role in tumorigenesis and tumor progression. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in blood are systemic inflammatory response markers. Some reports have showed that NLR and PLR are related to a poor prognosis in patients with lung cancer. However, little studies have reported whether NLR and PLR can be diagnostic markers for lung cancer. The aim of the current study is to investigate the roles of NLR and PLR in diagnosing lung cancer. Methods. This study analyzed data from lung cancer patients and healthy individuals in Wuxi People’s Hospital Affiliated with Nanjing Medical University. The Mann–Whitney U test was performed to compare differences between the lung cancer group and the control group. Based on white blood cell (WBC) counts, both lung cancer patients and healthy individuals were divided into the low-level group, moderate-level group, and high-level group. The Kruskal-Wallis test was applied to compare differences of NLR and PLR among those groups with different WBC counts. Spearman correlation analysis was used to assess correlations. Receiver operating characteristic (ROC) curves were performed to determine diagnostic accuracy. Results. 210 patients diagnosed with lung cancer and 261 healthy subjects were enrolled in this study. Levels of NLR and PLR increased in the lung cancer group compared with the control group ( P < 0.001 ). For the lung cancer group, NLR levels could rise with the increasing of WBC levels ( P < 0.001 ) while PLR levels had no significant variation with the increasing of WBC levels ( P = 0.206 ). For the control group, NLR levels could rise with the increasing of WBC levels ( P < 0.001 ) while PLR levels would decline with the increasing of WBC levels ( P < 0.001 ). In the lung cancer group, both NLR and PLR had no significant correlations with aspartate transaminase, urea, and glucose. The area under the curve (AUC) with 95% confidence interval (95% CI) of NLR and PLR to distinguish lung cancer patients from healthy subjects was, respectively, 0.684 (0.634-0.735) and 0.623 (0.571-0.674). When NLR and PLR were combined, AUC (95% CI) increased to 0.691 (0.642-0.740). Conclusions. NLR and PLR alone have moderate ability to distinguish lung cancer patients from healthy subjects. Furthermore, combination forms of NLR and PLR can improve diagnostic ability.

scholarly journals The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011

2015 ◽  
Vol 13 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Cinthia Leite Frizzera Borges Bognar ◽  
Sergio Daniel Simon ◽  
Rene Claudio Gansl ◽  
Roberto Abramoff ◽  
Marcelo Aisen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
General Hospital ◽  
Cell Lung Cancer ◽  
Current Literature ◽  
Demographic Data ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature. Results: A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference. Conclusion: We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.

Sign in / Sign up

Export Citation Format

Share Document